NCT01352988View on ClinicalTrials.gov

Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

February 28, 2014

Conditions
Lupus Erythematosus, Cutaneous
Interventions
DRUG

Fumaric acid esters

Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels

Trial Locations (1)

48149

Department of Dermatology, University Hospital Muenster, Münster

All Listed Sponsors
lead

University Hospital Muenster

OTHER

NCT01352988 - Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus | Biotech Hunter | Biotech Hunter